GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Net Margin %

MXCT (MaxCyte) Net Margin % : -121.90% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. MaxCyte's Net Income for the three months ended in Dec. 2024 was $-10.60 Mil. MaxCyte's Revenue for the three months ended in Dec. 2024 was $8.69 Mil. Therefore, MaxCyte's net margin for the quarter that ended in Dec. 2024 was -121.90%.

The historical rank and industry rank for MaxCyte's Net Margin % or its related term are showing as below:

MXCT' s Net Margin % Range Over the Past 10 Years
Min: -106.29   Med: -54.78   Max: -15.57
Current: -106.01


MXCT's Net Margin % is ranked worse than
80.22% of 819 companies
in the Medical Devices & Instruments industry
Industry Median: 0.38 vs MXCT: -106.01

MaxCyte Net Margin % Historical Data

The historical data trend for MaxCyte's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Net Margin % Chart

MaxCyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.15 -56.30 -53.25 -91.85 -106.29

MaxCyte Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.69 -83.99 -89.89 -141.56 -121.90

Competitive Comparison of MaxCyte's Net Margin %

For the Medical Devices subindustry, MaxCyte's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Net Margin % distribution charts can be found below:

* The bar in red indicates where MaxCyte's Net Margin % falls into.


;
;

MaxCyte Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MaxCyte's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-41.055/38.627
=-106.29 %

MaxCyte's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-10.597/8.693
=-121.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte  (NAS:MXCT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


MaxCyte Net Margin % Related Terms

Thank you for viewing the detailed overview of MaxCyte's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Executives
Douglas J Swirsky officer: Chief Financial Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
John Joseph Johnston director C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Stanley C Erck director 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Thomas M. Ross officer: EVP, Global Sales C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud officer: EVP and General Counsel C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler director, officer: President and CEO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen officer: Chief Scientific Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy officer: Chief Financial Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz officer: SVP and CAO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell director C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke director 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203